IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:24 2025-06-24 EDT			5-day change	1st Jan Change
11.00 ^GBX	-4.35%		-6.38%	-6.38%

06-10	Ixico cheers FDA approval for contractor Fujirebio's Alzheimer's test	AN
06-10	IXICO plc Announces FDA Clearance of New Alzheimer's Disease Blood Based Diagnostic Biomarker	CI

IXICO Plc Appoints Susan Lowther FCMA as Chief Financial Officer, Effective October 1, 2014

Published on 2014-09-17 at 02:01

IXICO plc announced that Susan Lowther FCMA has been appointed to the board as Chief Financial Officer with effect from October 1, 2014. Susan (aged 54) was previously Group Chief Financial Officer and a director of Novacyt SA.

Latest news about IXICO plc

Ixico cheers FDA approval for contractor Fujirebio's Alzheimer's test	06-10	AN
IXICO plc Announces FDA Clearance of New Alzheimer's Disease Blood Based Diagnostic Biomarker	06-10	CI
Ixico Notes Role in US FDA Nod for New Alzheimer's Disease Biomarker Test	06-10	MT
Ixico Assists First FDA Clearance Of Alzheimer's Diagnostic Biomarker	06-10	RE
IXICO plc, H1 2025 Earnings Call, May 20, 2025	05-21
IXICO plc Reports Earnings Results for the Half Year Ended March 31, 2025	05-20	CI
Ixico shares up amid positive outlook as interim loss narrows	05-20	AN
Earnings Flash (IXI.L) IXICO Reports Fiscal H1 Revenue GBP3.2M	05-20	MT
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Loss GBX-1.11	05-20	MT
IXICO Posts H1 Rev Up 26% To 3.2 Mln Stg	04-16	RE
Ixico plc Provides Revenue Guidance for the Year Ending 31 March 2025	04-16	CI
Ixico Secures Two New Contracts for Alzheimer's, Huntington's Disease Imaging Analysis	02-27	MT
IXICO plc Wins in Alzheimer's and Huntington's Disease	02-27	CI
Ixico Bags Imaging Services Deal with US Client	12-10	MT
IXICO plc Wins US Client Clinical Trial Contract	12-10	CI
IXICO plc, 2024 Earnings Call, Dec 05, 2024	12-05
IXICO plc, 2024 Earnings Call, Dec 04, 2024	12-04
IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2024	12-04	CI
Medical Imaging Group Ixico Completes Retail Offer	24-10-15	MT
Ixico raises GBP4 million in equity raise at premium price	24-10-09	AN
Ixico Conditionally Raises GBP4 Million via Fundraising	24-10-09	MT
Ixico to Raise Equity via Share Placement, Subscription; Plans Retail Offer	24-10-09	MT
Ixico shares soar as company eyes stronger revenue in second half	24-08-14	AN
Stocks stay upbeat ahead of US CPI data	24-08-14	AN
AIM WINNERS & LOSERS: Ixico expects to beat guidance on contract wins	24-08-14	AN

Chart IXICO plc

Duration

Period

IXI: Dynamic Chart

Company Profile

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

Employees

Sector

Biotechnology & Medical Research

Calendar

12-02 - Q4 2025 Earnings Release (Projected)

More about the company